Nouveautés dans la stratégie thérapeutique de la diverticulite sigmoïdienne [Current treatment strategies for sigmoid diverticulitis]

Treatment of colonic diverticular disease has evolved over the past years. Most episodes are simple and can be successfully treated with antibiotics alone. For complicated diverticulitis, a strong trend is developing towards less invasive therapies including interventional radiology and laparoscopic lavage in an effort to avoid the morbidity and discomfort of a diverting colostomy. Based on a better understanding of the natural history of the disease, the indication to prophylactic colectomy after a few episodes of simple diverticulitis has been seriously challenged. For those patients who need a colectomy, single port laparoscopy, NOTES and transanal specimen extraction are being proposed. However larger studies are needed to confirm the hypothetical advantages of these evolving techniques.

Current practice in neuropsychological outcome reporting after aneurysmal subarachnoid haemorrhage.

BACKGROUND: Neuropsychological deficits (NPD) are common in patients with aneurysmal subarachnoid haemorrhage (aSAH). NPD are one of the major limiting factors for patients with an otherwise acceptable prognosis for sustained quality of life. There are only a few studies reporting outcome after aSAH, which used a standardized neuropsychological test battery as a primary or secondary outcome measure. Aim of this study was to determine the current practice of reporting NPD following aSAH in clinical studies. METHODS: A MEDLINE analysis was performed using the search term "subarachnoid haemorrhage outcome". The latest 1,000 articles were screened. We recorded study design, number of patients, and the presence of neuropsychological outcome report. Additionally, the time of testing after aSAH, the neuropsychological tests administered, as well as the percentage of patients with NPD were analyzed. RESULTS: A total of 324 publications between 2009 and 2012 were selected for further review. Of those, 21 studies (6.5%) reported neuropsychological outcome, in 2,001 of 346,666 patients (0.6%). The assessment of NPD differed broadly using both subjective and objective cognitive evaluation, and a large variety of tests were used. CONCLUSION: Neuropsychological outcome is underreported, and there is great variety in assessment in currently published clinical articles on aSAH. Prospective randomized trials treating aSAH may benefit from implementing more comprehensive and standardized neuropsychological outcome measures. This approach might identify otherwise unnoticed treatment effects in future interventional studies of aSAH patients.

Pulse wave amplitude drops during sleep are reliable surrogate markers of changes in cortical activity

Rapport de synthèseLe syndrome d'apnées obstructives du sommeil (SAOS) est une pathologie respiratoire fréquente. Sa prévalence est estimée entre 2 et 5% de la population adulte générale. Ses conséquences sont importantes. Notamment, une somnolence diurne, des troubles de la concentration, des troubles de la mémoire et une augmentation du risque d'accident de la route et du travail. Il représente également un facteur de risque cardiovasculaire indépendant.Ce syndrome est caractérisé par la survenue durant le sommeil d'obstructions répétées des voies aériennes supérieures. L'arrêt ou la diminution d'apport en oxygène vers les poumons entraîne des épisodes de diminution de la saturation en oxygène de l'hémoglobine. Les efforts ventilatoires visant à lever l'obstacle présent sur les voies aériennes causent de fréquents réveils à l'origine d'une fragmentation du sommeil.La polysomnographie (PSG) représente le moyen diagnostic de choix. Il consiste en l'enregistrement dans un laboratoire du sommeil et en présence d'un technicien diplômé, du tracé électroencéphalographique (EEG), de l'électrooculogramme (EOG), de l'électromyogramme mentonnier (EMG), du flux respiratoire nasal, de l'oxymétrie de pouls, de la fréquence cardiaque, de l'électrocardiogramme (ECG), des mouvements thoraciques et abdominaux, de la position du corps et des mouvements des jambes. L'examen est filmé par caméra infrarouge et les sons sont enregistrés.Cet examen permet entre autres mesures, de déterminer les événements respiratoires obstructifs nécessaires au diagnostic de syndrome d'apnée du sommeil. On définit une apnée lors d'arrêt complet du débit aérien durant au moins 10 secondes et une hypopnée en cas, soit de diminution franche de l'amplitude du flux respiratoire supérieure à 50% durant au moins 10 secondes, soit de diminution significative (20%) de l'amplitude du flux respiratoire pendant au minimum 10 secondes associée à un micro-éveil ou à une désaturation d'au moins 3% par rapport à la ligne de base. La détection des micro-éveils se fait en utilisant les dérivations électroencéphalographiques, électromyographiques et électrooculographiques. Il existe des critères visuels de reconnaissance de ces éveils transitoire: apparition de rythme alpha (8.1 à 12.0 Hz) ou beta (16 à 30 Hz) d'une durée supérieure à 3 secondes [20-21].Le diagnostic de S AOS est retenu si l'on retrouve plus de 5 événements respiratoires obstructifs par heure de sommeil associés soit à une somnolence diurne évaluée selon le score d'Epworth ou à au moins 2 symptômes parmi les suivants: sommeil non réparateur, étouffements nocturne, éveils multiples, fatigue, troubles de la concentration. Le S AOS est gradué en fonction du nombre d'événements obstructifs par heure de sommeil en léger (5 à 15), modéré (15 à 30) et sévère (>30).La polysomnographie (PSG) comporte plusieurs inconvénients pratiques. En effet, elle doit être réalisée dans un laboratoire du sommeil avec la présence permanente d'un technicien, limitant ainsi son accessibilité et entraînant des délais diagnostiques et thérapeutiques. Pour ces mêmes raisons, il s'agit d'un examen onéreux.La polygraphie respiratoire (PG) représente l'alternative diagnostique au gold standard qu'est l'examen polysomnographique. Cet examen consiste en l'enregistrement en ambulatoire, à savoir au domicile du patient, du flux nasalrespiratoire, de l'oxymétrie de pouls, de la fréquence cardiaque, de la position du corps et du ronflement (par mesure de pression).En raison de sa sensibilité et sa spécificité moindre, la PG reste recommandée uniquement en cas de forte probabilité de SAOS. Il existe deux raisons principales à l'origine de la moindre sensibilité de l'examen polygraphique. D'une part, du fait que l'état de veille ou de sommeil n'est pas déterminé avec précision, il y a dilution des événements respiratoires sur l'ensemble de l'enregistrement et non sur la période de sommeil uniquement. D'autre part, en l'absence de tracé EEG, la quantification des micro-éveils est impossible. Il n'est donc pas possible dans l'examen poly graphique, de reconnaître une hypopnée en cas de diminution de flux respiratoire de 20 à 50% non associée à un épisode de désaturation de l'hémoglobine de 3% au moins. Alors que dans l'examen polysomnographique, une telle diminution du flux respiratoire pourrait être associée à un micro-éveil et ainsi comptabilisée en tant qu'hypopnée.De ce constat est né la volonté de trouver un équivalent de micro-éveil en polygraphie, en utilisant les signaux à disposition, afin d'augmenter la sensibilité de l'examen polygraphique.Or plusieurs études ont démontrés que les micro-éveils sont associés à des réactions du système nerveux autonome. Lors des micro-éveils, on met en évidence la survenue d'une vasoconstriction périphérique. La variation du tonus sympathique associée aux micro-éveils peut être mesurée par différentes méthodes. Les variations de l'amplitude de l'onde de pouls mesurée par pulsoxymétrie représentant un marqueur fiable de la vasoconstriction périphérique associée aux micro-réveils, il paraît donc opportun d'utiliser ce marqueur autonomique disponible sur le tracé des polygraphies ambulatoires afin de renforcer la sensibilité de cet examen.Le but de l'étude est d'évaluer la sensibilité des variations de l'amplitude de l'onde de pouls pour détecter des micro-réveils corticaux afin de trouver un moyen d'augmenter la sensibilité de l'examen polygraphique et de renforcer ainsi sont pouvoir diagnostic.L'objectif est de démontrer qu'une diminution significative de l'amplitude de l'onde pouls est concomitante à une activation corticale correspondant à un micro¬réveil. Cette constatation pourrait permettre de déterminer une hypopnée, en polygraphie, par une diminution de 20 à 50% du flux respiratoire sans désaturation de 3% mais associée à une baisse significative de l'amplitude de pouls en postulant que l'événement respiratoire a entraîné un micro-réveil. On retrouve par cette méthode les mêmes critères de scoring d'événements respiratoires en polygraphie et en polysomnographie, et l'on renforce la sensibilité de la polygraphie par rapport au gold standard polysomnographique.La méthode consiste à montrer en polysomnographie qu'une diminution significative de l'amplitude de l'onde de pouls mesurée par pulsoxymétrie est associée à une activation du signal électroencéphalographique, en réalisant une analyse spectrale du tracé EEG lors des baisses d'amplitude du signal d'onde de pouls.Pour ce faire nous avons réalisé une étude rétrospective sur plus de 1000 diminutions de l'amplitude de l'onde de pouls sur les tracés de 10 sujets choisis de manière aléatoire parmi les patients référés dans notre centre du sommeil (CIRS) pour suspicion de trouble respiratoire du sommeil avec somnolence ou symptomatologie diurne.Les enregistrements nocturnes ont été effectués de manière standard dans des chambres individuelles en utilisant le système d'acquisition Embla avec l'ensemble des capteurs habituels. Les données ont été par la suite visuellement analysées et mesurées en utilisant le software Somnologica version 5.1, qui fournit un signal de l'amplitude de l'onde de pouls (puise wave amplitude - PWA).Dans un premier temps, un technicien du sommeil a réalisé une analyse visuelle du tracé EEG, en l'absence des données du signal d'amplitude d'onde de pouls. Il a déterminé les phases d'éveil et de sommeil, les stades du sommeil et les micro¬éveils selon les critères standards. Les micro-éveils sont définis lors d'un changement abrupt dans la fréquence de l'EEG avec un pattern d'ondes thêta-alpha et/ou une fréquence supérieure à 16 Hz (en l'absence de fuseau) d'une durée d'au minimum trois secondes. Si cette durée excède quinze secondes, l'événement correspond à un réveil.Puis, deux investigateurs ont analysé le signal d'amplitude d'onde de pouls, en masquant les données du tracé EEG qui inclut les micro-éveils. L'amplitude d'onde de pouls est calculée comme la différence de valeur entre le zénith et le nadir de l'onde pour chaque cycle cardiaque. Pour chaque baisse de l'amplitude d'onde de pouls, la plus grande et la plus petite amplitude sont déterminées et le pourcentage de baisse est calculé comme le rapport entre ces deux amplitudes. On retient de manière arbitraire une baisse d'au moins 20% comme étant significative. Cette limite a été choisie pour des raisons pratiques et cliniques, dès lors qu'elle représentait, à notre sens, la baisse minimale identifiable à l'inspection visuelle. Chaque baisse de PWA retenue est divisée en 5 périodes contiguës de cinq secondes chacune. Deux avant, une pendant et deux après la baisse de PWA.Pour chaque période de cinq secondes, on a pratiqué une analyse spectrale du tracé EEG correspondant. Le canal EEG C4-A1 est analysé en utilisant la transformée rapide de Fourier (FFT) pour chaque baisse de PWA et pour chaque période de cinq secondes avec une résolution de 0.2 Hz. La distribution spectrale est catégorisée dans chaque bande de fréquence: delta (0.5 à 4.0 Hz); thêta (4.1 à 8.0Hz); alpha (8.1 à 12.0 Hz); sigma (12.1 à 16 Hz) et beta (16.1 à 30.0 Hz). La densité de puissance (power density, en μΥ2 ) pour chaque bande de fréquence a été calculée et normalisée en tant que pourcentage de la puissance totale. On a déterminé, ensuite, la différence de densité de puissance entre les 5 périodes par ANOVA on the rank. Un test post hoc Tukey est été utilisé pour déterminer si les différences de densité de puissance étaient significatives. Les calculs ont été effectués à l'aide du software Sigmastat version 3.0 (Systat Software San Jose, California, USA).Le principal résultat obtenu dans cette étude est d'avoir montré une augmentation significative de la densité de puissance de l'EEG pour toutes les bandes de fréquence durant la baisse de l'amplitude de l'onde de pouls par rapport à la période avant et après la baisse. Cette augmentation est par ailleurs retrouvée dans la plupart des bande de fréquence en l'absence de micro-réveil visuellement identifié.Ce résultat témoigné donc d'une activation corticale significative associée à la diminution de l'onde de pouls. Ce résulat pourrait permettre d'utiliser les variations de l'onde de pouls dans les tracés de polygraphie comme marqueur d'une activation corticale. Cependant on peut dire que ce marqueur est plus sensible que l'analyse visuelle du tracé EEG par un technicien puisque qu'on notait une augmentation de lactivité corticale y compris en l'absence de micro-réveil visuellement identifié. L'application pratique de ces résultats nécessite donc une étude prospective complémentaire.

Toxic substances in blood: an analysis of current recommendations under a Bayesian (decision) approach

This article extends existing discussion in literature on probabilistic inference and decision making with respect to continuous hypotheses that are prevalent in forensic toxicology. As a main aim, this research investigates the properties of a widely followed approach for quantifying the level of toxic substances in blood samples, and to compare this procedure with a Bayesian probabilistic approach. As an example, attention is confined to the presence of toxic substances, such as THC, in blood from car drivers. In this context, the interpretation of results from laboratory analyses needs to take into account legal requirements for establishing the 'presence' of target substances in blood. In a first part, the performance of the proposed Bayesian model for the estimation of an unknown parameter (here, the amount of a toxic substance) is illustrated and compared with the currently used method. The model is then used in a second part to approach-in a rational way-the decision component of the problem, that is judicial questions of the kind 'Is the quantity of THC measured in the blood over the legal threshold of 1.5 μg/l?'. This is pointed out through a practical example.

Changes in Aortic Pulse Wave Velocity in Hypertensive Postmenopausal Women: Comparison Between a Calcium Channel Blocker vs Angiotensin Receptor Blocker Regimen.

J Clin Hypertens (Greenwich). 2012;14:773-778. ©2012 Wiley Periodicals, Inc. Postmenopausal women are at greater risk for hypertension-related cardiovascular disease. Antihypertensive therapy may help alleviate arterial stiffness that represents a potential modifiable risk factor of hypertension. This randomized controlled study investigated the difference between an angiotensin receptor blocker and a calcium channel blocker in reducing arterial stiffness. Overall, 125 postmenopausal hypertensive women (age, 61.4±6 years; systolic blood pressure/diastolic blood pressure [SBP/DBP], 158±11/92±9 mm Hg) were randomized to valsartan 320 mg±hydrochlorothiazide (HCTZ) (n=63) or amlodipine 10 mg±HCTZ (n=62). The primary outcome was carotid-to-femoral pulse wave velocity (PWV) changes after 38 weeks of treatment. Both treatments lowered peripheral blood pressure (BP) (-22.9/-10.9 mm Hg for valsartan and -25.2/-11.7 mm Hg for amlodipine, P=not significant) and central BP (-15.7/-7.6 mm Hg for valsartan and -19.2/-10.3 mm Hg for amlodipine, P<.05 for central DBP). Both treatments similarly reduced the carotid-femoral PWV (-1.9 vs -1.7 m/s; P=not significant). Amlodipine was associated with a higher incidence of peripheral edema compared with the valsartan group (77% vs 14%, P<.001). BP lowering in postmenopausal women led to a reduction in arterial stiffness as assessed by PWV measurement. Both regimens reduced PWV to a similar degree after 38 weeks of treatment despite differences in central BP lowering, suggesting that the effect of valsartan on PWV is mediated through nonhemodynamic effects.

Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics.

Cardiovascular risk assessment might be improved with the addition of emerging, new tests derived from atherosclerosis imaging, laboratory tests or functional tests. This article reviews relative risk, odds ratios, receiver-operating curves, posttest risk calculations based on likelihood ratios, the net reclassification improvement and integrated discrimination. This serves to determine whether a new test has an added clinical value on top of conventional risk testing and how this can be verified statistically. Two clinically meaningful examples serve to illustrate novel approaches. This work serves as a review and basic work for the development of new guidelines on cardiovascular risk prediction, taking into account emerging tests, to be proposed by members of the 'Taskforce on Vascular Risk Prediction' under the auspices of the Working Group 'Swiss Atherosclerosis' of the Swiss Society of Cardiology in the future.

Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.

The major problems associated with the use of corticosteroids for the treatment of ocular diseases are their poor intraocular penetration to the posterior segment when administered locally and their secondary side effects when given systemically. To circumvent these problems more efficient methods and techniques of local delivery are being developed. The purposes of this study were: (1) to investigate the pharmacokinetics of intraocular penetration of hemisuccinate methyl prednisolone (HMP) after its delivery using the transscleral Coulomb controlled iontophoresis (CCI) system applied to the eye or after intravenous (i.v.) injection in the rabbit, (2) to test the safety of the CCI system for the treated eyes and (3) to compare the pharmacokinetic profiles of HMP intraocular distribution after CCI delivery to i.v. injection. For each parameter evaluated, six rabbit eyes were used. For the CCI system, two concentrations of HMP (62.5 and 150mg ml(-1)), various intensities of current and duration of treatment were analyzed. In rabbits serving as controls the HMP was infused in the CCI device but without applied electric current. For the i.v. delivery, HMP at 10mg kg(-1)as a 62.5mg ml(-1)solution was used. The rabbits were observed clinically for evidence of ocular toxicity. At various time points after the administration of drug, rabbits were killed and intraocular fluids and tissues were sampled for methylprednisolone (MP) concentrations by high pressure liquid chromatography (HPLC). Histology examinations were performed on six eyes of each group. Among groups that received CCI, the concentrations of MP increased in all ocular tissues and fluids in relation to the intensities of current used (0.4, 1.0 and 2.0mA/0.5cm(2)) and its duration (4 and 10min). Sustained and highest levels of MP were achieved in the choroid and the retina of rabbit eyes treated with the highest current and 10min duration of CCI. No clinical toxicity or histological lesions were observed following CCI. Negligible amounts of MP were found in ocular tissues in the CCI control group without application of current. Compared to i.v. administration, CCI achieved higher and more sustained tissue concentrations with negligible systemic absorption. These data demonstrate that high levels of MP can be safely achieved in intraocular tissues and fluids of the rabbit eye, using CCI. With this system, intraocular tissues levels of MP are higher than those achieved after i.v. injection. Furthermore, if needed, the drug levels achieved with CCI can be modulated as a function of current intensity and duration of treatment. CCI could therefore be used as an alternative method for the delivery of high levels of MP to the intraocular tissues of both the anterior and posterior segments.

Chirurgie endoscopique endonasale des tumeurs de la base du crane : historique, état de l'art et perspectives d'avenir [Shifting paradigm in skull base surgery: Roots, current state of the art and future trends of endonasal endoscopic approaches].

During the last two decades, endoscopic endonasal approach has completed the minimally invasive skull base surgery armamentarium. Endoscopic endonasal skull base surgery (EESBS) was initially developed in the field of pituitary adenomas, and gained an increasing place for the treatment of a wide variety of skull base pathologies, extending on the midline from crista galli process to the occipitocervical junction and laterally to the parasellar areas and petroclival apex. Until now, most studies are retrospective and lack sufficient methodological quality to confirm whether the endoscopic endonasal pituitary surgery has better results than the microsurgical trans-sphenoidal classical approach. The impressions of the expert teams show a trend toward better results for some pituitary adenomas with the endoscopic endonasal route, in terms of gross total resection rate and probably more comfortable postoperative course for the patient. Excepting intra- and suprasellar pituitary adenomas, EESBS seems useful for selected lesions extending onto the cavernous sinus and Meckel's cave but also for clival pathologies. Nevertheless, this infatuation toward endoscopic endonasal approaches has to be balanced with the critical issue of cerebrospinal fluid leaks, which constitutes actually the main limit of this approach. Through their experience and a review of the literature, the authors aim to present the state of the art of this approach as well as its limits.

Debris flows as a factor of hillslope evolution controlled by a continuous or a pulse process?

Flood effectiveness observations imply that two families of processes describe the formation of debris flow volume. One is related to the rainfall?erosion relationship, and can be seen as a gradual process, and one is related to additional geological/geotechnical events, those named hereafter extraordinary events. In order to discuss the hypothesis of coexistence of two modes of volume formation, some methodologies are applied. Firstly, classical approaches consisting in relating volume to catchments characteristics are considered. These approaches raise questions about the quality of the data rather than providing answers concerning the controlling processes. Secondly, we consider statistical approaches (cumulative number of events distribution and cluster analysis) and these suggest the possibility of having two distinct families of processes. However the quantitative evaluation of the threshold differs from the one that could be obtained from the first approach, but they all agree in the sense of the coexistence of two families of events. Thirdly, a conceptual model is built exploring how and why debris flow volume in alpine catchments changes with time. Depending on the initial condition (sediment production), the model shows that large debris flows (i.e. with important volume) are observed in the beginning period, before a steady-state is reached. During this second period debris flow volume such as is observed in the beginning period is not observed again. Integrating the results of the three approaches, two case studies are presented showing: (1) the possibility to observe in a catchment large volumes that will never happen again due to a drastic decrease in the sediment availability, supporting its difference from gradual erosion processes; (2) that following a rejuvenation of the sediment storage (by a rock avalanche) the magnitude?frequency relationship of a torrent can be differentiated into two phases, the beginning one with large and frequent debris flow and a later one with debris flow less intense and frequent, supporting the results of the conceptual model. Although the results obtained cannot identify a clear threshold between the two families of processes, they show that some debris flows can be seen as pulse of sediment differing from that expected from gradual erosion.

Transvaginal specimen extraction in colorectal surgery: current state of the art.

Aim  Background The expected benefit of transvaginal specimen extraction is reduced incision-related morbidity. Objectives A systematic review of transvaginal specimen extraction in colorectal surgery was carried out to assess this expectation. Method  Search strategy The following keywords, in various combinations, were searched: NOSE (natural orifices specimen extraction), colorectal, colon surgery, transvaginal, right hemicolectomy, left hemicolectomy, low anterior resection, sigmoidectomy, ileocaecal resection, proctocolectomy, colon cancer, sigmoid diverticulitis and inflammatory bowel diseases. Selection criteria Selection criteria included large bowel resection with transvaginal specimen extraction, laparoscopic approach, human studies and English language. Exclusion criteria were experimental studies and laparotomic approach or local excision. All articles published up to February 2011 were included. Results  Twenty-three articles (including a total of 130 patients) fulfilled the search criteria. The primary diagnosis was colorectal cancer in 51% (67) of patients, endometriosis in 46% (60) of patients and other conditions in the remaining patients. A concurrent gynaecological procedure was performed in 17% (22) of patients. One case of conversion to laparotomy was reported. In two patients, transvaginal extraction failed. In left- and right-sided resections, the rate of severe complications was 3.7% and 2%, respectively. Two significant complications, one of pelvic seroma and one of rectovaginal fistula, were likely to have been related to transvaginal extraction. The degree of follow up was specified in only one study. Harvested nodes and negative margins were adequate and reported in 70% of oncological cases. Conclusion  Vaginal extraction of a colorectal surgery specimen shows potential benefit, particularly when associated with a gynaecological procedure. Data from prospective randomized trials are needed to support the routine use of this technique.

Current state of vaccine therapies in non-small-cell lung cancer.

A large variety of cancer vaccines have undergone extensive testing in early-phase clinical trials. A limited number have also been tested in randomized phase II clinical trials. Encouraging trends toward increased survival in the vaccine arms have been recently observed for 2 vaccine candidates in patients with non-small-cell lung cancer. These have provided the impetus for the initiation of phase III trials in large groups of patients with lung cancer. These vaccines target 2 antigens widely expressed in lung carcinomas: melanoma-associated antigen 3, a cancer testis antigen; and mucin 1, an antigen overexpressed in a largely deglycosylated form in advanced tumors. Therapeutic cancer vaccines aim at inducing strong CD8 and CD4 T-cell responses. The majority of vaccines recently tested in phase I clinical trials show efficacy in terms of induction of specific tumor antigen immunity. However, clinical efficacy remains to be determined but appears limited. Efforts are thus aimed at understanding the basis for this apparent lack of effect on tumors. Two major factors are involved. On one hand, current vaccines are suboptimal. Strong adjuvant agents and appropriate tumor antigens are needed. Moreover, dose, route, and schedule also need optimization. On the other hand, it is now clear that large tumors often present a tolerogenic microenvironment that hampers effective antitumor immunity. The partial understanding of the molecular pathways leading to functional inactivation of T cells at tumor sites has provided new targets for intervention. In this regard, blockade of cytotoxic T-lymphocyte antigen-4 and programmed death-1 with humanized monoclonal antibodies has reached the clinical testing stage. In the future, more potent cancer vaccines will benefit from intense research in antigen discovery and adjuvant agents. Furthermore, it is likely that vaccines need to be combined with compounds that reverse major tolerogenic pathways that are constitutively active at the tumor site. Developing these combined approaches to vaccination in cancer promises new, exciting findings and, at the same time, poses important challenges to academic research institutions and the pharmaceutical industry.